Note: Descriptions are shown in the official language in which they were submitted.
CA 02277724 1999-08-12
-1-
A COMPOSIT::ON FOR INDUCING HUMORAL ANERGY TO AN
IMMUNOGEN
Technical Field
This nvent:ion is in the field of immunology
and concerns co~aposit:ians and methods for inducing
humoral anergy ~:or the purpose of treating antibody-
mediated pathologies.
Background of tree Invention
In order to survive in a world of pathogenic or
potentially pathogenic microorganisms, higher organisms
have evolved immune systems which can specifically
recognize virtually any foreign substance through its
characteristic molecules. This recognition frequently
results in the product=ion of specifis proteins called
antibodies which bind only to the foreign substance which
induced their synthesis, causing the elimination of the
invading microorganism. Occasionally an animal's immune
system makes ant:ibodieas which recognize some of its own
molecules, generating an autoimmune state that may affect
the animal's health adversely.
The ir~duction of specific antibodies in
response to an i.mmunoc~en involves the interaction of
multiple cell types, ~.ncluding thymus-derived lymphocytes
(T cells), macraphage;~, and bone marrow-derived
lymphocytes (B c:ells).. B cells possess surface
immunoglobulin by which they are able to bind immunogens,
CA 02277724 1999-08-12
-2-
the first step in their activation and clonal expansion.
The site(s), region,(s) or domains) of the immunogen to
which the immunoglobulin binds is called a "B cell
epitope". In the second step of B cell activation and
expansion, T cells are activated through interaction with
the B cell bound-immunogen at a site, region or domain of
the immunogen called a "T cell epitope". Once activated,
the T cells provide: positive signals) to the B cells
bound by the immunogen and they proceed to differentiate
and to produce and secrete antibody. Positive signals
from the T cell include the secretion of lymphokines,
and/or direct contact between the B cells and T cells.
T cell epitopes may be different or more restricted in
scope than B cell epitopes. As discussed above, in order
for an immunogen to elicit T dependent antibodies, it
must have epitopes recognized by both B and T cells.
Past attempts to treat antibody-mediated
pathologies have involved both general and specific
suppression of the immune response. General suppression
has typically employed broad spectrum, nonspecific
immunosuppressants such as cyclophosphamide or steroids.
Because these nonspecific drugs suppress many aspects of
the immune system, they eliminate its required and
beneficial functions as well as the malfunction causing
the condition being treated. They are thus used with
extreme caution if at all, and subject the patient to
risk from secondary infections or other undesirable side
effects.
Because of the disadvantages of general
immunosuppression, methods for specifically suppressing
an immune response to an immunogen without affecting the
normal functions of the immune system are highly
preferred for treating antibody-mediated pathologies.
The present invention concerns compositions and methods
CA 02277724 1999-08-12
-3-
for specifically suppressing the humoral response to
immunogens.
Prior att=empts to induce specific
immunosuppre~;sion have focused on conjugating haptens and
immunogens to nonimmunogenic polymeric carriers.
Benacerraf, R;atz and their colleagues used conjugates of
haptens and antigens and copolymers of D-lysine and D-
glutamic acid (D-E1~). Their initial studies involved
conjugates of the synthetic hapten 2,4-dinitrophenyl
(DNP) in guinea pigs and mice and showed the conjugates
were capable of inc3ucing humoral unresponsiveness. These
initial studies were then extended to conjugates of other
haptens and conjugates of immunogens. While the results
with haptens were :repeatable, and although their patents
(U.S. 4,191,Ei68 and 4,220,565) allege the approach is
effective in inducing tolerance to immunogens, subsequent
work has shoGrn that conjugates of D_-EK and immunogens do
not provide a means for inducing humoral unresponsiveness
to the immunogen. For instance, Liu et al., J. Immun.
(1979) 123:25456-2464, report that subsequent studies of
those conjugates demonstrate that the conjugates "do not
induce unresponsiveness at the level of protein specific
B cells." Spmilarly, Butterfield et al., J. Allercry
Clin. Immun. (1981) 67:272-278, reported that conjugates
of ragweed inamunogen and D-EK actually stimulated both
IgE and IgG responses to the immunogen.
This subsequent work and other data dealing
with conjugates of nonimmunogenic polymers and immunogens
(Saski et al.., Scand. J. Immun. (1982) 16:191-200; Sehon,
Prog. Allerm~ (1982) 32:161-202; Wilkinson et al., J.
Immunol._ (987) 139:326-331, and Borel et al., J. Immunol.
Methods (1990) 126:159-168) appear to indicate that the
anergy, if any, obtained with such conjugates is due to
suppression of T cell activity, not B cell
unresponsiveness.
CA 02277724 1999-08-12
-4-
Several other references deal with conjugates
of nonimmunogenic po:Lymers and DNA. See U.S. 4,191,668;
U.S. 4,650,625; J. C:Lin. Invest. (1988) 82:1901-1907. -
As. a whole, these references indicate that
these DNA conjugates may suppress the production of
antibodies to this lupus autoimmunogen. It should be
noted in this regard that DNA, like haptens, does not
possess T cell epitopes.
In su.m, applicants believe the prior art shows
that antibody ~~roduct:ion to conjugates of nonimmunogenic
stable polymers and haptens or DNA, neither of which have
T cell epitopes~, may provide B cell unresponsiveness.
Applicants also believe that conjugates of immunogens
do not provide B cell unresponsiveness but may
activate T cells to directly suppress the immune
response.
Disclosure of the Invention
The present: invention resides in the discovery
that the failure of t:he prior conjugates of
nonimmunogenic stable polymers and immunogens to induce B
cell anergy (unresponsiveness) was due to the fact that
the immunogens contained both B and T cell epitopes and
that if the latter were eliminated, the conjugate would
be effective for inducing B cell anergy.
35
I II I
CA 02277724 2002-08-23
- 5 -
According to an aspect of the invention, there is provided a conjugate for
inducing specific B cell anergy to an immunogen implicated in an antibody-
mediated pathology in an individual suffering from said pathology comprising a
nonimmunogenic carrier and an analog of the immunogen wherein (a) the analog
binds specifically to surface antibody on B cells to which the immunogen binds
specifically and (b) the conjugate lacks T cell epitopes capable of activating
T
cells in said individual.
The analog may be selected from the group consisting of peptides,
polypeptides, proteins, glycoproteins, lipoproteins, carbohydrates, lipids,
and
polysaccharides.
The immunogen may be an external immunogen, for example, a biological
drug, allergen or a D immunogen associated with Rh hemolytic disease.
The immunogen may be a self-immunogen, for example a self immunogen
that is associated with thyroiditis, diabetes, stroke, male infertility,
myasthenia
gravis or rheumatic fever.
The immunogen and the analog may be of the same chemical class, for
example, polypetides or may be of different chemical classes.
The carrier is a polymer, for example, a copolymer of D-lysine and D-
glutamic acid, polyethylene glycol or triethylene glycol.
The carrier may have three to eight attachment sites.
The antibody-mediated pathology may be an autoimmune disorder.
According to another aspect of the invention, there is provided a
pharmaceutical composition for treating an antibody-mediated pathology
comprising a therapeutically effective amount of the conjugate described above
combined with a pharmaceutically acceptable carrier.
According to another aspect of the invention, there is provided the use of
an effective amount of the above-described composition for inducing specific B
cell anergy to a T cell-dependent immunogen in an individual.
i ii i
CA 02277724 2002-08-23
- Sa -
According to another aspect of the invention, there is provided the use of a
therapeutically effective amount of the above-described composition for
treating
an individual for an antibody-mediated pathology in which undesired antibodies
are produced in response to a T cell-dependent immunogen.
Brief Description of the Drawings
Figure 1 graphically illustrates the detection of B cell epitopes in immunized
CAF1 mice as described in Example 1.
Figure 2, similarly, illustrates the detection of T cell epitopes as described
in Example 1.
Figure 3 illustrates the suppression of antibodies to peptide "L-53" as
described in Example 1.
Figures 4 and 5 are graphs of the results described in Example 4.
Modes for Carryina Out the Invention
As used herein the term "B cell anergy" intends unresponsiveness of those
B cells requiring T cell help to produce and secrete antibody and includes,
without
limitation, clonal deletion of immature and/or mature B cells and/or the
inability of
B cells to produce antibody. "Unresponsiveness" means a therapeutically
effective
reduction in the humoral response to an immunogen. Quantitatively the
reduction
(as measured by
CA 02277724 1999-08-12
-6-
reduction in antibody production) is at least 50%,
preferably at least 75%, and most preferably 100%.
"A:ntibody" means those antibodies which are
T cell dependent .
As used herein the term "immunogen" means a
chemical entity that elicits a humoral immune response
when injected into an animal. Immunogens have both B
cell epitopes and T cell epitopes.
As used herein "individual" denotes a member of
the mammalian species and includes humans, primates,
domestic animals such as cattle and sheep, sports animals
such as horses, anal pets such as dogs and cats.
The terms "analog" of an immunogen intends a
molecule that (a) binds specifically to an antibody to
which the immunoge,n binds specifically and (b) lacks T
cell epitopes. Although the analog will normally be a
fragment or derivative of the immunogen and thus be of
the same chemical class as the immunogen (e.g., the
immunogen is a polypeptide and the analog is a
polypeptide), chemical similarity is not essential.
Accordingly, the analog may be of a different chemical
class than t:he immunogen (e.g., the immunogen is a
carbohydrate and the analog is a polypeptide) as long as
it has the functional characteristics (a) and (b) above.
The analog may be a protein, carbohydrate, lipid,
lipoprotein, glycoprotein, lipopolysaccharide or other
biochemical entity. Further, the chemical structure of
neither the immunogen nor the analog need be defined for
the purposes of this invention.
"Nonimmu.nogenic" is used to describe the
carrier polymer means that the carrier polymer elicits
substantially no immune response when it is administered
by itself to an individual.
Immunoge:ns that are involved in antibody
mediated pathologies may be external (foreign to the
CA 02277724 1999-08-12
-7-
individual) immunogens such as biological drugs,
allergens, idiopathic contrast media, and the like or
self-immunogens (autoimmunogens) such as those associated
with thyroiditis (t:hyroglobulin), stroke (cardiolipin),
male infertility (cc-sperm), myasthenia gravis
(acetylcholine receptor), rheumatic fever (carbohydrate
complex), and. Rh hemolytic disease (D immunogen).
Analogs t:o such immunogens may be identified by
screening candidate molecules to determine whether they
(a) bind specifica7Lly to serum antibodies to the
immunogen and. (b) .Lack T cell epitopes. Specific binding
to serum antibodies may be determined using conventional
immunoassays and the presence or absence of T cell
epitopes may be determined by conventional T cell
activation assays. In this regard an analog Which "binds
specifically"' to serum antibodies to the immunogen
exhibits a reasonable affinity thereto. The presence or
absence of T cell epitopes may be determined using the
tritiated th~znidine incorporation assay described in the
examples. Analogs that fail to induce statistically
significant incorporation of thymidine above background
are deemed to lack T cell epitopes. It will be
appreciated that the quantitative amount of thymidine
incorporation may ~~ary with the immunogen. Typically a
stimulation index below about 2-3, more usually about
1-2, is indicative of a lack of T cell epitopes.
A normal first step in identifying useful
analogs is to prepare a panel or library of candidates to
screen. For instance, in the case of protein or peptide
analogs, libraries may be made by synthetic or
recombinant techniques such as those described by Geysen
et al. in ~itheti~~ Peptides as Antigens; Ciba Symposium
(1986) 119:1'_!1-149; Devlin et al., Science (1990)
249:404-406; Scott et al., Science (1990) 249:386-390;
and Cwirla et. al., PNAS USA (1990) 87:6378-6382. In one
CA 02277724 1999-08-12
_g_
synthetic technique, peptides of about 5 to 30 amino
acids are synthesized in such a manner that each peptide
overlaps the next <ind all linear epitopes are
represented. This is accomplished by overlapping both
the carboxyl and amino termini by one less residue than
that expected for a B cell epitope. For example, if the
assumed minimum requirement for a B cell epitope is six
amino acids, then each peptide must overlap the
neighboring peptides by five amino acids. In this
embodiment, each peptide is then screened against
antisera produced against the native immunogen, either by
- immunization of animals or from patients, to identify the
presence of B cell epitopes. Those molecules with
antibody binding activity are then screened for the
presence of ~~ cell epitopes as described in the examples.
The molecules lacking T cell epitopes are useful as
analogs in the invention.
If the T cell epitope(s) of an immunogen are
known or can be identified, random screening of candidate
analogs is not necessary. In such instances, the T cell
epitope(s) may be altered (e. g., by chemical
derivatization, or elimination of one or more components
of the epito~~e) to render them inoperative or be
eliminated completely, such as, for instance, in the case
of peptides, by synthetic or recombinant procedures.
The analogs are coupled to a nonimmunogenic
polymeric carrier to prepare the conjugates of the
invention. l?referred polymeric carriers are biologically
stable, i.e., they exhibit an in vivo excretion half-
life of days to months, and are preferably composed of a
synthetic single chain of defined composition. They will
normally have a molecular weight in the range of about
5,000 to abort 200,000, preferably 5,000 to 30,000.
Examples of ouch polymers are polyethylene glycol, poly-
D-lysine, polyvinyl alcohol, polyvinyl pyrrolidone,
CA 02277724 1999-08-12
_g-
immunoglobulins, and "D-EK", a copolymer of D-glutamic
acid and D-lysine. :Particularly preferred carrier
polymers are D--EKs having a molecular weight of about
5,000 to about 30,000, and an E:K (D-glutamic acid:D-
lysine) mole ratio o:f approximately 60:40,
Conjugation of the analog to the carrier
polymer may be effected in any number of ways, typically
involving one or more crosslinking agents and functional
groups on the analog and carrier.
PolyF~eptid~a analogs will contain amino acid
sidechain groups such as amino, carbonyl, or sulfhydryl
groups that will serape as sites for coupling the analog
to the carrier. Res:idues.that have such functional
groups may be aidded ito the analog if the analog does not
already contain same. Such residues may be incorporated
by solid phase synthesis techniques or recombinant
techniques, both of which are well known in the peptide
synthesis arts. In the case of carbohydrate or lipid
analogs, functional amino and sulfhydryl groups may be
incorporated therein by conventional chemistry. For
instance, primary amino groups may be incorporated by
reaction with eahylendiamine in the presence of sodium
cyanoborohydridle and sulfhydryls may be introduced by
reaction of cys;teamine dihydrochloride followed by
reduction with a standard disulfide reducing agent. In a
similar fashion the carrier may also be derivatized to
contain functional groups if it does not already possess
appropriate functional groups. With specific reference
to conjugating peptide analogs and D-EK or other
proteinaceous carriers; coupling is preferably carried
out using a het.erobil:unctional crosslinker, such as
sulfosuccinimid.yl(4-iodoacetyl) aminobenzoate, which
links the a amino group on the D-lysine residues of D-EK
CA 02277724 1999-08-12
-10-
to a sulfhydryl side chain from an amino terminal
cysteine residue on the peptide to be coupled. This
method is preferably carried out such that an average of
3 to 5 analog molecules are coupled to each D-EK molecule
and the average mo:Lecular weight of the D-EK prior to
coupling is ~~, 000 1~a 30, 00o daltons.
The conjugates will normally be formulated for
administration by :injection (e. g., intraperitoneally,
intramuscularly, etc.). Accordingly, they will typically
be combined urith pharmaceutically acceptable carriers
such as saline, Ringer's solution, dextrose solution, and
the like. The conjugate will normally constitute about
0.01% to 10% by weight of the formulation. The conjugate
is administered to an individual in a "therapeutically
effective amount", i.e., an amount sufficient to produce
B cell anerg~~ to the involved immunogen and effect
prophylaxis, improvement or elimination of the antibody-
mediated condition being addressed. The particular
dosage regims:n, i.~e., dose, timing and repetition, will
depend on ths~ particular individual and that individual's
medical history. lKormally, a dose of about 10 ~cg to 1 mg
conjugate/kg body weight will be given, daily for three
consecutive days. Other appropriate dosing schedules
would be 3 doses per week, or one dose per week.
Repetitive administrations, normally timed according to B
cell turnover rates, may be required to achieve and/or
maintain a state of humoral anergy. Such repetitive
administrations will typically involve treatments of up
to 1 mg/kg oj° body weight every 30 to 60 days, or sooner,
if an increa:~e in antibody titer is detected.
Alternativel~r, sustained continuous release formulations
of the conjugates 'may be indicated for some pathologies.
Various formulations and devices for achieving sustained
release are known in the art.
CA 02277724 1999-08-12
-11-
Anti-~T helper cell treatments may be
administered tc>gether with the conjugates. Such
treatments usually employ agents that suppress T cells
such as steroic;s or c:yclosporin.
The following examples are intended to further
illustrate the invention and its uniqueness. These
examples are nat internded to limit the scope of the
invention in any manner.
Example 1
B Cell A.neray to the Acetylcholine Receptor
Preparation of Peptides and D-EK/Peptide
Conjugates:
The a-subunit of the acetylcholine receptor of
Torpedo californicus is described by Stroud, R.M., and
Finer-Moore, J., Ann. Rev. Cell Biol. (1985) 1:317:351,
and Sumikawa, K., et al., Nucl. Acids Res. (1982)
10:5809-22. The peptide defined by residues 47-127 of
that a-subunit is called the major immunogenic region
(MIR).. .
Two peptidea, L-42 and L-53, corresponding to
residues 61-77 and 11.2-127 of that a-subunit, were
synthesized using conventional solid-phase methods and
purified to homogeneity by HPLC. An amino terminal
cysteine was added to each sequence for the purpose of
attachment of the peptide to D-EK via a thio ether
linkage.
Each peptide (40 mg) was dissolved in 0.1M
sodium borate buffer, pH 9Ø The solution was reacted
with citraconic anhydride (400 ~,L) at room temperature;
the pH was maintained. above 7.0 by addition of 1M NaOH.
The solution was then. made 20 mM in dithiothreitol and
was warmed at 37°C for 20 minutes to reduce the peptide.
The mixture was quickly desalted over G-10 Sephadex*-
*Trademark
CA 02277724 1999-08-12
-12-
columns which. were equilibrated with O.1M sodium borate,
pH 7Ø
D-E;K (200 mg, weight average mw = 10, 000 -
30,000) was dissolved in 2.0 mL of O.1M sodium borate.
Sulfosuccinim.idyl (4-iodoacetyl) aminobenzene (SSIAB,
mg, Pierce. Chemical) was added to the mixture and the
mixture was reacted for 90 minutes at room temperature in
the dark. Th.e mixture was then desalted over a 10 mL
G-25 column, equilibrated with O.1M sodium borate,
10 pH 7Ø
The: desalted SSIAB-D-EK was mixed with the
reduced and desalted peptide and reacted overnight. The
resulting conjugates was placed in dialysis tubing with a
14 Kd cutoff and was dialyzed against 5% acetic acid to
remove citrac:onyl groups. The dialysis buffer was
changed to ph,osphai:e-buffered saline and the dialysis
continued.
Detection of B cell epitopes:
CAf1 mice were immunized (day 0)
intraperitone:ally (i.p.) with 50 ~g of recombinant
torpedo MIR absorbed onto alum plus B. pertussis vaccine
(Iverson, G.M., (1986) Handbook of Experimental
ImmunoloaY, V'ol. 2" p. 67, D.M. Weir ed., Blackwell
Scientific Puiblicai=ions, Palo Alto, CA). The mice
received a booster injection of the same protein in
saline, IP, on day 21 and were bled from the tail vein on
day 28. Sera. from these mice (anti-MIR sera) were used
to screen peptides L-42 and L-53 for the presence of B
cell epitopes;, as i~ollows. The sera were added to
microtiter wells coated with 10 ~.g/ml of the indicated
peptide conjugates.. The plates were incubated at 37°C
for one hour, washead 3 times, 100 ~,1 of alkaline
phosphatase-conjugated goat antimouse antibody was added,
incubated at 37°C for one hour, washed 3 times, and
100 ~,1 of developer (substrate) was added to each well.
CA 02277724 1999-08-12
-13-
The plates were incubated at room temperature for 30
minutes and the amount of color in each well was
determined in a Ti.tertek~ Multiskan. Results are
illustrated graphically in Figure 1. The curve labelled
"L42 or L53, NMS" contains the values obtained using
normal mouse serum (NMS) instead of the anti-MIR sera on
plates coated with either L42 or L53. As shown in Figure
1, both peptides reacted specifically with antibodies
from the immunized mice indicating the presence of B cell
epitopes on both peptides.
Detection of T cell epitopes:
T cell activation was assayed by the general
procedure of Bradley, M.L., (1980) in Mishell and Shigii,
eds., Selected Methods in Cellular Immunoloay (W. H.
Freeman and Co., ~~an Francisco, CA), p. 164. CAF1 mice
were immunized on the footpad with 50 ~g MIR in Complete
Freund's Adjuvant (CFA) on day 0. On day 7 the popliteal
lymph nodes were removed and placed in culture in
microtiter plates using 5 x 105 cells per well. The
peptides or peptide-DEK conjugate were added to the
cultures, and on day 4, 1 ~Ci of tritiated thymidine was
added to each well. to measure proliferation of T cells.
The cultures were harvested on day 5 with a Skatron~ cell
harvester. The amount of incorporated 3H-thymidine was
determined in a Beckman L6800~ liquid scintillation
counter. The stimulation index was calculated by
dividing the CPM incorporated with peptide by the CPM
incorporated from cultures without any peptide. A
stimulation index > 1 was indicative of the presence of a
T cell epitope on the peptide added to the well. As
shown in Figure 2, L-42 but not L-53 possessed T cell
epitopes in this assay.
CA 02277724 1999-08-12
-14-
Induction of B Cell Anergy to L-53 by L-53/D-
EK Conjugate:
CAF1 mice. were immunized with 50 ~g of MIR,
i.p., absorbed onto alum plus B. pertussis vaccine on
day 0. On days 21,. 22 and 23 the mice (6 mice per group)
received 10 or 100 ug of either L-42-D-EK conjugate or
L-53-D-EK con.jugate. One group received only saline. On
day 28 all mice received a booster injection of MIR in
saline and on. day 35 all mice were bled and assayed for
the presence of antibodies to L-42 and L-53 in their
sera, using an ELISA assay as described above with
respect to Figure .1. The results for antibodies to L42
are shown in Figure. 3A and for antibodies to L53 are
shown in Figure 3B" The L-53 conjugate suppressed
antibody formation to L-53 but not to L-42. The L-42
conjugate did. not suppress the antibody response to
either L-42 or L-53 but rather may have increased
antibody production to L-42. The antibody titers are
expressed as a percent of a standard sera. The P values
were determined by a standard t test comparing each dose
to the saline: control.
Examgle 2
Failure o7: Ovalbumin-D-EK Coniuc~ate to
Induce B Cell Anerqy to Ovalbumin
This example is further evidence that
conjugates of immunogens and D-EK do not induce B cell
anergy.
Synthesis of Ovalbumin-D-EK Conjugate:
Chicken egg ovalbumin (50 mg) was dissolved in
5 mL of O.1M sodium borate buffer, pH 9.0, containing 10
mM EDTA. After the addition of 3.0 mg of 2-iminothiolane
(Traut's reagent), the mixture was reacted for 2.5 hours
at room temperature. D-EK (54 mg), dissolved in 0.5M
sodium borate:, pH X3.0, at a concentration of 100 mg/mL,
CA 02277724 1999-08-12
-15-
was reacted wit;! SSIAB (18 mg; Pierce Chemical) for 2.5
hours in the dark, at room temperature. The two reaction
mixtures described above were desalted separately on G-
25 columns (Pha:rmacia; 10 mL column volume, equilibrated
with O.1M sodium borate, pH 9.0) and the excluded
fractions were ~~ombined and reacted for 16 hours at 4°C,
in the dark. The reaction product was fractionated by
*..
gel filtration aver Sephacryl ~-200 (490 mL, Pharmacia)
columns, equilibrated with 0.2M ammonium bicarbonate.
l0 Fractions containing conjugate, as assessed by
polyacrylamide ~~el electrophoresis, in the presence of
sodium dodecyl aulfate (SDS-PAGE), were pooled and dried
under vacuum. 'rhe dried material was reacted with 0.8 mL
of citraconic anhydride, maintaining the pH between 7 and
9 by the addition of 1M NaOH, in order to efficiently
separate conjugated ovalbumin from unreacted protein.
The citraconylal~ed conjugate was rechromatographed over
S-200, and fracl=ions containing high molecular weight
material (> 80,000 daltons), as assessed SDS-PAGE, were
used for biolog:ecal studies. ,
ChickESn _ovalbumin, when conjugated to D-EK,
does not induce B cell anergy in mice immunized to
chicken ovalbumin:
FemalEa CAF1 mice were primed with chicken
ovalbumin (ova; 100 ~C~g/mouse, i.p.) precipitated on alum,
with B. gertussis vaccine added as an adjuvant. Sixteen
weeks later, the. mice were divided into two groups of six
mice each. One group (control) was treated with saline,
and the second croup was injected with a conjugate of ova
and D-EK (ova-D--EK; 200 ~Cg/mouse/day, i.p.). The mice
were dosed on three successive days. One week after the
first dose, the mice .in both groups were boosted, i.p.,
with ova in saline (100 ~g/mouse). One week later, the
mice were bled f=rom a tail vein. The plasma was
harvested and a~~sayed f.or the amount of anti-ova
*Trademark
CA 02277724 1999-08-12
-16-
antibodies b~T an ELISA assay. As shown in Table 1, the
ova-D-EK con;jugate did not suppress the anti-ova
response.
Table 1
Percent ~f Anti-Ova
Group Treatment Standard Serum ~ S.D.
1 saline 70.7 ~ 36
2 ova-D-EK 160.2 ~ 167
1 The amount of anti-ova antibody was determined in an
ELISA, measured against a standard pool of sera
obtained from CAF1 mice immunized and boosted with
ova. The values shown are the mean and standard
deviation for the six mice in each group.
Example 3
lFailure of MIR-D-EK Conjuq"ate to
Induce B Cell Anercty to MIR
This example is still further evidence that
conjugates o:E immunogens and D-EK do not induce B cell
anergy.
Synthesis of MIR-D-EK Conjugate:
MII~ was modified on its carboxyl-terminus to
include a sequence of 8-amino acids (Arg-Ser-Lys-Ser-
Lys-Ser-Lys-Cys (SEQ. ID NO.: 1)). The amino-terminus
was extended by one amino acid, proline. Purified
modified MIR (250 mg) was reduced with 100 mM
dithiothreit«1 and was desalted over Sephadex G-25
(Pharmacia), equilibrated with 0.1 M sodium borate
buffer, pH 9.0, containing 10 mM EDTA. D-EK (400 mg) was
reacted with SSIAB (29 mg) as in the previous examples.
The product Haas desalted over G-25. The excluded volumes
from the modified MIR and D-EK G-25 column runs were
CA 02277724 1999-08-12
-17-
combined and reactE=_d at 4°C for 16 hours, in the dark.
Excess SSIAB group, were quenched with 2-mercaptoethanol,
and the reaction mixture was concentrated to 20 mL over a
PM-10 membrane (Am:icon Corporation). The mixture was
treated with 1.0 mL of citraconic anhydride and
chromatographed over S-300 (Pharmacia; 1.8 L),
equilibrated with !5% ammonium hydroxide. Fractions
containing two or more modified MIR groups per D-EK, as
assessed by f~DS-PA~sE, were pooled and used for biological
studies.
MIR-D-EK conjugate contains T cell epitopes in
rats immunized witlh MIR from the same species:
T cell activation was assayed by the general
procedure of Bradley, supra. Female Lewis rats were
immunized in the footpad with MIR (50 fig) in complete
Freund's adjuvant (CFA) on day 0. On day 7, the
popliteal lymph nodes were removed and placed in culture
in microtitei plates using 5~105 cells per well. MIR-D-
EK was added,, and, after four days of culture, the wells
were pulsed with t:ritiated thymidine (1-uCi) to measure
proliferation of T cells. The cultures were collected
after 5 days of culture with a Skatron"' cell harvester.
The amount oi° incorporated 3H-thymidine was determined by
scintillation spectrometry. The stimulation index was
calculated bit dividing the counts incorporated in the
absence of the conjugate. A stimulation index of greater
than 1 Was considered indicative of the presence of a T
cell epitope on the added conjugate. The stimulation
index was 4 or _greater at all concentrations of MIR-D-EK
tested (10 ~cc~/mL to 400 mg/mL). This proves that T cells
from MIR-immunized rats recognize T cell epitopes on the
MIR-D-EK con:jugate :in this assay.
CA 02277724 1999-08-12
-18-
MIR-D-EK does not induce B cell anergy in rats
immunized with MIR:
Female Lewis rats were primed with MIR (100
~Cg/rat) in CfA. S.ix months later, the rats were divided
into three groups of three rats each. One group was
treated with saline (control) and the other two groups
were treated with 1KIR-D-EK (100 ~Cg/rat, i.p.) on three
successive days. ,after one week, the rats in the control
group and one, group that had been treated with MIR-D-EK
were boosted with :recombinant MIR (1000 ~,g/rat, i.p.) in
saline. One week later, all three groups of rats were
bled from then tail vein. The plasma was harvested and
assayed for i:he amount of anti-MIR antibodies by an ELISA
assay. TablEa 2 below reports the data from those assays.
Table 2
Group Treai:ment MIR Boost ~g/ml anti-MIR2 P vs.
(mean ~ S.D.) Group 1
1 Saline Yes 130.5 ~ 74.7
2 MIR-D-EK Yes 85.5 t 31.1 0.195
3 MIR-D-EK No 230.6 ~ 31 0.049
2 The conceni~ration of anti-MIR antibodies was determined
in an ELISA measured against a standard pool of rat
anti-MIR sera. The values shown are the mean and
standard deviation of the three rats in each group.
P values ware determined by a Standard t test. Group 2
is not significantly different from Group 1. Group 3
(the non-b«osted group) is significantly higher than
3 0 Group 1.
As shown in Table 2, the data on Group 1
animals (saline control) indicate that MIR itself is an
immunogen. 'rhe data for the Group 2 and 3 animals
indicate that the M:IR-D-EK conjugate did not affect the
CA 02277724 1999-08-12
-I9-
anti-MIR response. In fact, MIR-D-EK boosted the anti-
MIR response in Group 3.
Example 4
Tests with ConiuQate of L-42 and KLH
These tempts, taken together with the results of
Example 1 show that: the moiety conjugated to D-EK will
cause anergy in B cells recognizing that moiety if the
moiety either does not contain a T cell epitope or is not
recognized by T ce7~.ls.
Synthesis of L42 peptide-KLH conjugate:
Reduced h-42 (see Example 1) was conjugated to
keyhole limpet hemocyanin (KLH) using thioether chemistry
similar to that de:~cribed above with respect to D-EK.
L-42 laci;s a T cell epitope(s) in mice
immunized with L-4:?-KLH:
Activation of T cells by peptides was measured
by the general procedure of Bradley, sutra. Female CAF1
mice were ima:unized in the footpad with L-42 peptide
conjugated KI~H (L-~~2-KLH; 50 fig) in CFA on day 0. On day
7, the poplit:eal lymph nodes were removed and placed in
culture in mi.crotii~er plates, at a cell density of 5'10 5
cells/well. Peptides were added, and, after four days of
culture, the wells were pulsed with 1 ~Ci of tritiated
thymidine to measure proliferation of T cells. The
cultures were: collEacted after 5 days of culture with a
SkatronT" cell. harvEaster. The amount of incorporated 3H-
thymidine wa~~ determined by scintillation spectrometry.
The stimulation index was calculated by dividing the
counts incorF~orated in the absence of peptide. An index
of greater than 1 :is indicative of the presence of a T
cell epitope on the added peptide.
The: data in Figure 4 demonstrate that the L-42
did not stimulate the growth of T cells taken from L-42
KLH-immunized mice, and therefore did not contain an
CA 02277724 1999-08-12
-20-
epitope(s) recognized by T-cells induced by immunization
with L-42-KLF~.
L-~E2-D-E:K conjugate induces a B cell anergy in
mice immunizs~d to :L-42-KLH:
CA3?1 mice were primed with 100 ~g/mouse of L-
42-KLH on alum plus B. pertussis vaccine as an adjuvant.
Three weeks :Later, the mice were divided into groups of
six mice eactl. One group was treated by i.p. injections
on three successive days with saline (control); the other
groups were :similarly treated with L-42-KLH (50 ~g/mouse,
i.p.), and, after a wait of one week, they were bled from
the tail vein. The plasma was harvested and assayed for
the amount o~° anti-L-42 and anti-KLH antibodies by ELISA
assays. Data are expressed as a percent of a standard
serum. An a:~terisk indicates that a data point was
significantllt different from the control as determined by
a standard t test.
The= data in Figure 5 demonstrate that the L-42
response, bui~ not the anti-KLH response, was suppressed
in this assay by the L-42-D-EK conjugate. Thus, the
studies summarized :in Example 1 and these data
demonstrate i~he L-42-D-EK induces B cell anergy when the
mice are immunized in a manner that does not induce the
proliferation of T cell clones that recognize the L-42
peptide. On the other hand, L-42-D-EK did not induce
B cell anerg!~ in animals that were immunized with an
immunogen (M:IR) which induced T cells that recognized the
L-42 peptide.
Modifications of the above-described modes for
carrying out the invention that are obvious to those of
ordinary sk ill in the fields of immunology, chemistry,
medicine and related arts are untended to be within the
scope of the following claims.
